Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 5/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21354694 | 0.92 | AR (0.34) | MEN1HPGDKMT2AARACSS2 | |
| SCHEMBL30315588 | 0.92 | AR (0.34) | MEN1HPGDKMT2AARACSS2 | |
| SCHEMBL18791698 | 0.91 | ACSS2 (0.36) | HPGDARACSS2PKMCEPT1 | |
| SCHEMBL18791697 | 0.91 | ACSS2 (0.36) | HPGDARACSS2PKMCEPT1 | |
| SCHEMBL20110989 | 0.91 | ACSS2 (0.36) | HPGDARACSS2PKMCEPT1 | |
| SCHEMBL21354593 | 0.86 | AR (0.34) | HPGDARACSS2RORC | |
| SCHEMBL30315429 | 0.86 | AR (0.34) | HPGDARACSS2RORC | |
| SCHEMBL21354647 | 0.84 | KCNQ3 (0.35) | MEN1HPGDKMT2ANPSR1RORC | |
| SCHEMBL27254418 | 0.82 | JAK2 (0.33) | HPGDRORC | |
| SCHEMBL21354733 | 0.81 | JAK2 (0.33) | ARCETPRORCPDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | MEN1 1284/4885HPGD 4074/4885KMT2A 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.